Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial

BACKGROUND: SARS-CoV-2, the virus that causes COVID-19, enters the cells through a mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein highly expressed in the lungs. The putative viral-induced inhibition of ACE2 could result in the defective degradation of bradyki...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Trials
मुख्य लेखकों: Mansour, Eli, Bueno, Flávia F., de Lima-Júnior, José C., Palma, Andre, Monfort-Pires, Milena, Bombassaro, Bruna, Araujo, Eliana P., Bernardes, Ana Flavia, Ulaf, Raisa G., Nunes, Thyago A., Ribeiro, Luciana C., Falcão, Antônio Luís E., Santos, Thiago Martins, Trabasso, Plinio, Dertkigil, Rachel P., Dertkigil, Sergio S., Maia, Rafael P., Benaglia, Tatiana, Moretti, Maria Luiza, Velloso, Licio A.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2021
विषय:
Study Protocol
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7816150/
https://ncbi.nlm.nih.gov/pubmed/33472675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-021-05027-9
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन